Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Bayer Yakuhin Finds 85 Further Cases of Unreported ADRs
August 2, 2017
- No Policy Change in Obtaining Regulatory Approval of Nesp Biosimilar through New Firm: Kyowa Kirin President
August 1, 2017
- August FDA Filing Planned for FGF23 Antibody Burosumab: Kyowa Kirin
July 31, 2017
- Abilify-Jzoloft Combo Filed in Japan: Otsuka
July 31, 2017
- Kyowa Kirin Enjoys Higher Earnings on Benralizumab License Revenue
July 31, 2017
- AZ Labor Tribunal with 3 Employees Falls Apart, Civil Suit to Begin
July 31, 2017
- Rohto to Commence Clinical Trial of Regenerative Medicine Product for Hepatic Cirrhosis
July 31, 2017
- Mitsubishi Tanabe Begins Japan PII/III for Dyskinesia Med
July 28, 2017
- Astellas to Move Away from ADCs, Shuts Agensys Research Operations
July 28, 2017
- 3 Generic Makers Ordered to Pay Damages over Oxarol Patent Infringement
July 28, 2017
- Takeda Gets Rights to Tesaro’s PARP Inhibitor in Japan, Other Markets
July 28, 2017
- Chugai Nets Half-Year Revenue Rise on Milestone Income
July 28, 2017
- Fycompa Approved for Monotherapy for Partial Epilepsy in US
July 28, 2017
- Takeda, BioSurfaces Hook Up on Devices for GI Diseases
July 27, 2017
- Fujifilm to Invest 500 Million Yen in Bonac; Will Engage in Joint Research to Discover Nucleic Acid Medicines
July 27, 2017
- Linzess Off to Solid Start, Astellas Eyes Big Indication Addition
July 26, 2017
- Lenvatinib Filed for HCC in US and EU after Japan Submission
July 26, 2017
- AZ Japan to Work to Create “Frameworks for Success”: Commercial Excellence Head
July 26, 2017
- Sumitomo Dainippon to Invest up to US$10 Million in Investment Partnership
July 26, 2017
- Janssen to Sell Tapenta License to Mundipharma in Japan
July 25, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…